Biomarkers in Cancer Detection, Diagnosis, and Prognosis

Overview

Journal Sensors (Basel)

Publisher MDPI

Specialty Biotechnology

Date 2024 Jan 11

PMID 38202898

Authors

Sreyashi Das

Mohan Kumar Dey

Ram Devireddy

Manas Ranjan Gartia

Affiliations

Soon will be listed here.

Abstract

Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis, prognosis, treatment response, and personalized medicine. They serve as objective indicators, enabling early detection and intervention, leading to improved patient outcomes and reduced costs. Biomarkers also guide treatment decisions by predicting disease outcomes and facilitating individualized treatment plans. They play a role in monitoring disease progression, adjusting treatments, and detecting early signs of recurrence. Furthermore, biomarkers enhance drug development and clinical trials by identifying suitable patients and accelerating the approval process. In this review paper, we described a variety of biomarkers applicable for cancer detection and diagnosis, such as imaging-based diagnosis (CT, SPECT, MRI, and PET), blood-based biomarkers (proteins, genes, mRNA, and peptides), cell imaging-based diagnosis (needle biopsy and CTC), tissue imaging-based diagnosis (IHC), and genetic-based biomarkers (RNAseq, scRNAseq, and spatial transcriptomics).

Citing Articles

cfDNA hydroxymethylcytosine profiling for detection metastasis and recurrence of Esophageal Squamous Cell Carcinoma.

Kuerban S, Chen H, Chen L, Zhang L, Li X, Zhen B World J Surg Oncol. 2025; 23(1):90.

PMID: 40089765 DOI: 10.1186/s12957-025-03747-9.

Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review.

Salahi-Niri A, Zarand P, Mansouri N, Rastgou P, Yazdani O, Esbati R Health Sci Rep. 2025; 8(3):e70412.

PMID: 40051490 PMC: 11882395. DOI: 10.1002/hsr2.70412.

Alterations in expression of miRNA 497 and long non-coding RNAS (XIST-TSIX) and its significant role in colorectal cancer prediction.

El-Magied M, Fawzy A, Mostafa M, Elnaggar G, Moselhy S, Elhady M Sci Rep. 2025; 15(1):7387.

PMID: 40032945 PMC: 11876683. DOI: 10.1038/s41598-025-90110-3.

Therapeutic Potential of Medicinal Plants and Their Phytoconstituents in Diabetes, Cancer, Infections, Cardiovascular Diseases, Inflammation and Gastrointestinal Disorders.

Ansari P, Reberio A, Ansari N, Kumar S, Khan J, Chowdhury S Biomedicines. 2025; 13(2).

PMID: 40002867 PMC: 11853317. DOI: 10.3390/biomedicines13020454.

Recent Advances in SAW Sensors for Detection of Cancer Biomarkers.

Aleixandre M, Horrillo M Biosensors (Basel). 2025; 15(2).

PMID: 39996991 PMC: 11852368. DOI: 10.3390/bios15020088.

References

Meng E, Mitra A, Tripathi K, Finan M, Scalici J, McClellan S . ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS One. 2014; 9(9):e107142. PMC: 4162571. DOI: 10.1371/journal.pone.0107142. View

Andre T, Cohen R, Salem M . Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. Am Soc Clin Oncol Educ Book. 2022; 42:1-9. DOI: 10.1200/EDBK_349557. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Cindolo L, Benvenuto G, Salvatore P, Pero R, Salvatore G, Mirone V . galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer. 1999; 84(1):39-43. DOI: 10.1002/(sici)1097-0215(19990219)84:1<39::aid-ijc8>3.0.co;2-e. View

Nava G, Madrigal Perez L . Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer. Expert Rev Mol Diagn. 2022; 22(4):439-447. DOI: 10.1080/14737159.2022.2065196. View

Amador-Ortiz C, Chen L, Hassan A, Frater J, Burack R, Nguyen T . Combined core needle biopsy and fine-needle aspiration with ancillary studies correlate highly with traditional techniques in the diagnosis of nodal-based lymphoma. Am J Clin Pathol. 2011; 135(4):516-24. DOI: 10.1309/AJCP3WZ8ZDRJQDOU. View

Arrington A, Heinrich E, Lee W, Duldulao M, Patel S, Sanchez J . Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012; 13(10):12153-68. PMC: 3497263. DOI: 10.3390/ijms131012153. View

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P . Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002; 160(5):1745-54. PMC: 1850868. DOI: 10.1016/S0002-9440(10)61121-2. View

Koc M, Wiles T, Weinhold D, Rightmyer S, Weaver A, McDowell C . Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance. J Mass Spectrom Adv Clin Lab. 2023; 30:51-60. PMC: 10709509. DOI: 10.1016/j.jmsacl.2023.11.001. View

10.

Gatti G, Vilardo L, Musa C, Di Pietro C, Bonaventura F, Scavizzi F . Role of Lamin A/C as Candidate Biomarker of Aggressiveness and Tumorigenicity in Glioblastoma Multiforme. Biomedicines. 2021; 9(10). PMC: 8533312. DOI: 10.3390/biomedicines9101343. View

11.

Mathieu V, Martin de Lassalle E, Toelen J, Mohr T, Bellahcene A, Van Goietsenoven G . Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol. 2012; 132(9):2245-54. DOI: 10.1038/jid.2012.142. View

12.

Piao H, Guo S, Wang Y, Zhang J . Exosomal Long Non-Coding RNA CEBPA-AS1 Inhibits Tumor Apoptosis and Functions as a Non-Invasive Biomarker for Diagnosis of Gastric Cancer. Onco Targets Ther. 2020; 13:1365-1374. PMC: 7034294. DOI: 10.2147/OTT.S238706. View

13.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

14.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

15.

Weissenbacher T, Kuhn C, Mayr D, Pavlik R, Friese K, Scholz C . Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. Anticancer Res. 2011; 31(2):451-7. View

16.

Humphrey P . Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 2004; 17(3):292-306. DOI: 10.1038/modpathol.3800054. View

17.

Hsu D, Dowling C, Jeng K, Chen J, Yang R, Liu F . Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 1999; 81(4):519-26. DOI: 10.1002/(sici)1097-0215(19990517)81:4<519::aid-ijc3>3.0.co;2-0. View

18.

Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y . MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol. 2012; 41(3):869-75. PMC: 3582905. DOI: 10.3892/ijo.2012.1535. View

19.

Jimenez-Luna C, Torres C, Ortiz R, Dieguez C, Martinez-Galan J, Melguizo C . Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget. 2018; 9(23):16573-16587. PMC: 5893263. DOI: 10.18632/oncotarget.24654. View

20.

Vallabhajosula S, Killeen R, Osborne J . Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010; 40(4):220-41. DOI: 10.1053/j.semnuclmed.2010.02.004. View